219 related articles for article (PubMed ID: 12649091)
1. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease.
Fredrikson GN; Hedblad B; Berglund G; Alm R; Ares M; Cercek B; Chyu KY; Shah PK; Nilsson J
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):872-8. PubMed ID: 12649091
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.
Schiopu A; Bengtsson J; Söderberg I; Janciauskiene S; Lindgren S; Ares MP; Shah PK; Carlsson R; Nilsson J; Fredrikson GN
Circulation; 2004 Oct; 110(14):2047-52. PubMed ID: 15451805
[TBL] [Abstract][Full Text] [Related]
3. Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women.
Fagerberg B; Prahl Gullberg U; Alm R; Nilsson J; Fredrikson GN
PLoS One; 2015; 10(3):e0120744. PubMed ID: 25768285
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.
Fredrikson GN; Söderberg I; Lindholm M; Dimayuga P; Chyu KY; Shah PK; Nilsson J
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):879-84. PubMed ID: 12649092
[TBL] [Abstract][Full Text] [Related]
5. Identification of autoantibodies in human plasma recognizing an apoB-100 LDL receptor binding site peptide.
Fredrikson GN; Berglund G; Alm R; Nilsson JA; Shah PK; Nilsson J
J Lipid Res; 2006 Sep; 47(9):2049-54. PubMed ID: 16809787
[TBL] [Abstract][Full Text] [Related]
6. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques.
Gonçalves I; Gronholdt ML; Söderberg I; Ares MP; Nordestgaard BG; Bentzon JF; Fredrikson GN; Nilsson J
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1250-5. PubMed ID: 15831809
[TBL] [Abstract][Full Text] [Related]
7. Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.
Asciutto G; Dias NV; Edsfeldt A; Alm R; Fredrikson GN; Gonçalves I; Nilsson J
Atherosclerosis; 2015 Apr; 239(2):289-94. PubMed ID: 25682025
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis.
Karvonen J; Päivänsalo M; Kesäniemi YA; Hörkkö S
Circulation; 2003 Oct; 108(17):2107-12. PubMed ID: 14530200
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
10. Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events.
Prasad A; Clopton P; Ayers C; Khera A; de Lemos JA; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1213-1221. PubMed ID: 28473443
[TBL] [Abstract][Full Text] [Related]
11. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis.
Sämpi M; Ukkola O; Päivänsalo M; Kesäniemi YA; Binder CJ; Hörkkö S
J Am Coll Cardiol; 2008 Oct; 52(17):1370-8. PubMed ID: 18940525
[TBL] [Abstract][Full Text] [Related]
12. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease.
Fredrikson GN; Hedblad B; Berglund G; Alm R; Nilsson JA; Schiopu A; Shah PK; Nilsson J
Stroke; 2007 May; 38(5):1495-500. PubMed ID: 17363723
[TBL] [Abstract][Full Text] [Related]
13. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.
McLeod O; Silveira A; Fredrikson GN; Gertow K; Baldassarre D; Veglia F; Sennblad B; Strawbridge RJ; Larsson M; Leander K; Gigante B; Kauhanen J; Rauramaa R; Smit AJ; Mannarino E; Giral P; Humphries SE; Tremoli E; de Faire U; Ohrvik J; Nilsson J; Hamsten A
Atherosclerosis; 2014 Jan; 232(1):242-8. PubMed ID: 24401246
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction.
Vallejo J; Dunér P; Fredrikson GN; Nilsson J; Bengtsson E
J Intern Med; 2017 Dec; 282(6):496-507. PubMed ID: 28944562
[TBL] [Abstract][Full Text] [Related]
15. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
[TBL] [Abstract][Full Text] [Related]
16. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension.
Su J; Georgiades A; Wu R; Thulin T; de Faire U; Frostegård J
Atherosclerosis; 2006 Sep; 188(1):160-6. PubMed ID: 16307748
[TBL] [Abstract][Full Text] [Related]
17. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
[TBL] [Abstract][Full Text] [Related]
18. Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects.
Engelbertsen D; Vallejo J; Quách TD; Fredrikson GN; Alm R; Hedblad B; Björkbacka H; Rothstein TL; Nilsson J; Bengtsson E
J Immunol; 2015 Oct; 195(7):3020-5. PubMed ID: 26290603
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against various forms of mildly oxidized low-density lipoprotein are not associated with carotid intima-media thickness in patients with primary hyperlipidemia.
Tsouli SG; Kiortsis DN; Xydis V; Argyropoulou MI; Elisaf M; Tselepis AD
Angiology; 2006; 57(5):615-22. PubMed ID: 17067985
[TBL] [Abstract][Full Text] [Related]
20. Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions.
Gonçalves I; Nitulescu M; Ares MP; Fredrikson GN; Jansson B; Li ZC; Nilsson J
Atherosclerosis; 2009 Jul; 205(1):96-100. PubMed ID: 19150065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
